This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nooijen, P. T. G. A. Articles by Ruiter, D. J. Search for Related Content PubMed PubMed Citation Articles by Nooijen, P. T. G. A. Articles by Ruiter, D. J.

Complete Response of Melanoma-in-Transit Metastasis after Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan without Massive Tumor Necrosis: A Clinical and Histopathological Study of the Delayed-Type Reaction Pattern¹

Department of Pathology, University Hospital Nijmegen, NL-6500 HB Nijmegen, the Netherlands [P. T. G. A. N., L. S., R. M. W. d. W., D. J. R.], and Departments of Surgery [A. M. M. E.] and Pathology [S. H-L], Dr. Daniel den Hoed Cancer Center, University Hospital Rotterdam, Groene Hilledÿk 301, NL-3075 EA Rotterdam, the Netherlands

Treatment of stage IIIA/B melanoma patients by isolated limb perfusion (ILP) with a combination of tumor necrosis factor- (TNF-) and melphalan induces a complete response in 80–90% of the cases. The mechanism of tumor regression induced by the combination of TNF- and melphalan is not precisely understood. Previous studies focused on the immediate (i.e., within a few days) clinico-pathological changes after perfusion involving hemorrhagic necrosis. However, clinical data clearly indicate that complete tumor remission frequently requires a period of a few weeks to as much as months after ILP. Because the mechanism underlying this delayed-type reaction is completely unknown, we studied the clinico-pathological events in patients with such slowly regressing melanoma lesions. For this purpose, 94 biopsies of in-transit melanoma metastasis that were taken sequentially from 11 patients between 1 week and 9 months after ILP were analyzed by light and electron microscopy and immunohistochemistry. Clinical data included patient sex, age, anatomical localization and size of the tumor, and follow-up. All of the 11 patients ultimately responded to perfusion treatment (9 complete, 1 partial, 1 stable disease). Serial biopsies showed scattered individual tumor cell necrosis without hemorrhage. Most of the lesions with this delayed-type reaction pattern were less than 0.5 cm in diameter. They contained varying amounts of histologically viable-looking tumor cells and tumor-infiltrating melanophages. In addition, a marked but transient infiltrate of peritumoral eosinophils and moderate interstitial edema and dermal fibrosis were encountered. Only small numbers of lymphocytes were present. In comparison with the reaction pattern after treatment with melphalan alone, the delayed-type reaction pattern was similar but more intense. The scattered tumor cell necrosis in the latter type may be explained by a TNF--induced increase in permeability of the tumor vascular bed, which results in higher intratumoral concentrations of melphalan or in a prolongation of its effect. Subsequently, degenerated tumor cells are cleared by macrophages, and, finally, repair by fibrosis occurs. Because the immediate reaction type is evoked by hyperpermeability of the tumor vessels as well, quantitative differences seem to determine which reaction type ensues. We suggest that the extent of tumor vasculature that is sensitive to TNF- determines the onset and histopathological pattern of tumor regression after ILP.

¹ This study was supported by Grant NKB 93-659 from the Dutch Cancer Society.

² To whom requests for reprints should be addressed, at Department of Pathology, University Hospital Nijmegen, P.O. Box 9101, NL-6500 HB Nijmegen, the Netherlands. Phone: 31-024-3614314; Fax: 31-24-3540520.

Received 1/26/98. Accepted 8/18/98.

This article has been cited by other articles:

				W. R. Cornett, L. M. McCall, R. P. Petersen, J. E. Herndon II, and D. S. Tyler In Reply J. Clin. Oncol., April 10, 2007; 25(11): 1450 - 1451. [Full Text] [PDF]

				A. J. Hayes, S. J. Neuhaus, M. A. Clark, and J. M. Thomas Isolated Limb Perfusion With Melphalan and Tumor Necrosis Factor {alpha} for Advanced Melanoma and Soft-Tissue Sarcoma Ann. Surg. Oncol., January 1, 2007; 14(1): 230 - 238. [Abstract] [Full Text] [PDF]

				C. Menon, M. Iyer, I. Prabakaran, R. J. Canter, S. C. Lehr, and D. L. Fraker TNF-alpha downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H317 - H329. [Abstract] [Full Text] [PDF]

				M. Clauss, C. Sunderkotter, B. Sveinbjornsson, S. Hippenstiel, A. Willuweit, M. Marino, E. Haas, R. Seljelid, P. Scheurich, N. Suttorp, et al. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability Blood, March 1, 2001; 97(5): 1321 - 1329. [Abstract] [Full Text] [PDF]